Yves Jongen, IBA’s Chief Research Officer and Managing Director, said: "IBA is committed to supporting the research efforts of OncoRay towards even better treatment deliveries. We are delighted and honored to benefit from their expertise in pioneering the use of our new technology. Their demonstrations of the accuracy of the device and integration within the clinical workflow are driving our developments to ensure the clinical efficiency of the Prompt Gamma solution.”
About Proton Therapy
Proton Therapy is considered the most advanced and targeted cancer radiotherapy treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor, sparing healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of side effects and long term complications, thereby improving patient outcomes and quality of life. Today, more than half of all proton therapy clinical facilities worldwide are equipped with IBA systems. This includes 18 proton therapy centers currently in operation and 16 additional centers under development.
Ad Statistics
Times Displayed: 113072
Times Visited: 6738 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
While proton therapy today represents less than 1% of radiotherapy treatments, studies estimate that more than 17% of patients treated by radiotherapy would benefit from being treated by this technique.
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal fullscale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.
Headquartered in Belgium and employing about 1100 people worldwide, IBA has installed systems across the world, from Europe and the US to emerging markets. IBA is listed on the panEuropean stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba worldwide.com
About OncoRay
In 2005, OncoRay was established as a Center for Innovation in Radiation Oncology in Dresden, in the framework of the "Create Excellence – Foster Talent" program of the German Federal Ministry of Education and Research. Building on the international reputation and extensive research infrastructure of the Dresden group, OncoRay, the “Center for Radiation Research in Oncology,” represents a new, futureoriented research effort in the field of radiation research in oncology. OncoRay is operated with the support of the Medical Faculty of the University of Technology of Dresden, the University Hospital Carl Gustav Carus and the HelmholtzZentrum DresdenRossendorf. The focus and strategy of OncoRay are aimed at the practical need for preclinical and clinical translational research in radiation oncology.
Back to HCB News
